Febrile episodes and documented infections during 90 days after the start of treatment
| . | VSAA group (n = 46) . | G-CSF+ group (n = 33) . | G-CSF− group (n = 31) . |
|---|---|---|---|
| No. patients | |||
| Documented infections | 11 | 8 | 7 |
| Severe infection (grade 3 or 4) | |||
| Bacteremia | 4 | 0 | 0 |
| Pneumonia | 3 | 1 | 0 |
| Spleen abcess | 1 | 0 | 0 |
| Interstitial pneumonitis | 1 | 1 | 1 |
| Mild to moderate infection (grade 1 or 2) | |||
| Cellulitis | 1 | 0 | 0 |
| Urinary tract infection | 0 | 1 | 0 |
| Perianal abscess | 0 | 1 | 0 |
| Otitis media | 0 | 0 | 1 |
| Herpes zoster | 1 | 3 | 3 |
| Herpes simplex | 0 | 0 | 2 |
| Mumps | 0 | 1 | 0 |
| Febrile days (≥38°C) | |||
| Median (range) | 7 (1-49) | 3 (1-9) | 3 (1-39) |
| . | VSAA group (n = 46) . | G-CSF+ group (n = 33) . | G-CSF− group (n = 31) . |
|---|---|---|---|
| No. patients | |||
| Documented infections | 11 | 8 | 7 |
| Severe infection (grade 3 or 4) | |||
| Bacteremia | 4 | 0 | 0 |
| Pneumonia | 3 | 1 | 0 |
| Spleen abcess | 1 | 0 | 0 |
| Interstitial pneumonitis | 1 | 1 | 1 |
| Mild to moderate infection (grade 1 or 2) | |||
| Cellulitis | 1 | 0 | 0 |
| Urinary tract infection | 0 | 1 | 0 |
| Perianal abscess | 0 | 1 | 0 |
| Otitis media | 0 | 0 | 1 |
| Herpes zoster | 1 | 3 | 3 |
| Herpes simplex | 0 | 0 | 2 |
| Mumps | 0 | 1 | 0 |
| Febrile days (≥38°C) | |||
| Median (range) | 7 (1-49) | 3 (1-9) | 3 (1-39) |